- HK$13.17bn
- HK$19.30bn
- CNY6.06bn
- 18
- 54
- 84
- 52
Annual cashflow statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 942 | -74.6 | 670 | 700 | 839 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 371 | 661 | 455 | 399 | 429 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -791 | -986 | -142 | -206 | -1,891 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,033 | 182 | 1,654 | 1,595 | 168 |
Capital Expenditures | -1,520 | -1,542 | -1,164 | -1,165 | -1,708 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1,658 | -1,894 | -495 | -253 | 237 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 138 | -3,436 | -1,658 | -1,418 | -1,471 |
Financing Cash Flow Items | -933 | 1,241 | 720 | 397 | 871 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 254 | 1,879 | 54.1 | 842 | 2,956 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,538 | -1,427 | -115 | 915 | 1,698 |